المؤلفون: Villarroel-Vicente C; Department of Pharmacology, University of Valencia, 46100 Burjassot, Valencia, Spain; Institute of Health Research-INCLIVA, University Clinic Hospital of Valencia, 46010 Valencia, Spain., García A; Department of Pharmacology, University of Valencia, 46100 Burjassot, Valencia, Spain; Institute of Health Research-INCLIVA, University Clinic Hospital of Valencia, 46010 Valencia, Spain., Zibar K; Univ Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U-1011-EGID, F-59000 Lille, France., Schiel MA; Facultad de Química, Bioquímica y Farmacia, Universidad Nacional de San Luis-IMIBIO-SL-CONICET, Chacabuco 915, San Luis, Argentina., Ferri J; Service of Endocrinology and Nutrition, University Clinic Hospital of Valencia, 46010 Valencia, Spain., Hennuyer N; Univ Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U-1011-EGID, F-59000 Lille, France., Enriz RD; Facultad de Química, Bioquímica y Farmacia, Universidad Nacional de San Luis-IMIBIO-SL-CONICET, Chacabuco 915, San Luis, Argentina., Staels B; Univ Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U-1011-EGID, F-59000 Lille, France., Cortes D; Department of Pharmacology, University of Valencia, 46100 Burjassot, Valencia, Spain; Institute of Health Research-INCLIVA, University Clinic Hospital of Valencia, 46010 Valencia, Spain. Electronic address: dcortes@uv.es., Cabedo N; Department of Pharmacology, University of Valencia, 46100 Burjassot, Valencia, Spain; Institute of Health Research-INCLIVA, University Clinic Hospital of Valencia, 46010 Valencia, Spain. Electronic address: nuria.cabedo@uv.es.

المصدر: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2024 Jul 01; Vol. 106, pp. 129770. Date of Electronic Publication: 2024 Apr 26.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9107377 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-3405 (Electronic) Linking ISSN: 0960894X NLM ISO Abbreviation: Bioorg Med Chem Lett Subsets: MEDLINE

مواضيع طبية MeSH: Metabolic Syndrome*/drug therapy , Metabolic Syndrome*/metabolism , Quinolines*/chemistry , Quinolines*/pharmacology , Quinolines*/chemical synthesis, Structure-Activity Relationship ; Humans ; Peroxisome Proliferator-Activated Receptors/metabolism ; Peroxisome Proliferator-Activated Receptors/agonists ; Molecular Structure ; Lipopolysaccharides/pharmacology ; Lipopolysaccharides/antagonists & inhibitors ; Anti-Inflammatory Agents/chemical synthesis ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/chemistry ; Macrophages/drug effects ; Macrophages/metabolism ; Dose-Response Relationship, Drug ; Benzopyrans/pharmacology ; Benzopyrans/chemical synthesis ; Benzopyrans/chemistry ; Animals ; Mice

المؤلفون: Bakr RB; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, 62514, Egypt., El Azab IH; Department of Food Science and Nutrition, College of Science, Taif University, P.O. Box: 11099, 21944, Taif, Saudi Arabia., Elkanzi NAA; Chemistry Department, College of Science, Jouf University, P.O. Box: 2014, Sakaka, Saudi Arabia.; Chemistry Department, Faculty of Science, Aswan University, P.O. Box: 81528, Aswan, Egypt.

المصدر: Chemistry & biodiversity [Chem Biodivers] 2024 Jun; Vol. 21 (6), pp. e202400200. Date of Electronic Publication: 2024 May 08.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Verlag Helvetica Chimica Acta Country of Publication: Switzerland NLM ID: 101197449 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1612-1880 (Electronic) Linking ISSN: 16121872 NLM ISO Abbreviation: Chem Biodivers Subsets: MEDLINE

مواضيع طبية MeSH: Quinolines*/chemistry , Quinolines*/pharmacology , DNA Gyrase*/metabolism , DNA Gyrase*/chemistry , Microbial Sensitivity Tests* , Molecular Docking Simulation* , Tetrahydrofolate Dehydrogenase*/metabolism , Tetrahydrofolate Dehydrogenase*/chemistry , Candida albicans*/drug effects , Anti-Bacterial Agents*/pharmacology , Anti-Bacterial Agents*/chemistry , Anti-Bacterial Agents*/chemical synthesis, Structure-Activity Relationship ; Antifungal Agents/pharmacology ; Antifungal Agents/chemistry ; Antifungal Agents/chemical synthesis ; Pyrimidines/chemistry ; Pyrimidines/pharmacology ; Pyrimidines/chemical synthesis ; Molecular Structure ; Topoisomerase II Inhibitors/pharmacology ; Topoisomerase II Inhibitors/chemistry ; Topoisomerase II Inhibitors/chemical synthesis ; Dose-Response Relationship, Drug

المؤلفون: Zhou BJ; Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Suzhou 215006,China., Wang WS; Department of Interventional Radiology, Kunshan First People's Hospital,Suzhou 215300, China., Yin Y; Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Suzhou 215006,China., Yang J; Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Suzhou 215006,China., Zhu XL; Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Suzhou 215006,China., Ni CF; Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Suzhou 215006,China.

المصدر: Zhonghua nei ke za zhi [Zhonghua Nei Ke Za Zhi] 2024 Aug 01; Vol. 63 (8), pp. 769-775.

نوع المنشور: English Abstract; Journal Article

بيانات الدورية: Publisher: Zhonghua yi xue hui Country of Publication: China NLM ID: 16210490R Publication Model: Print Cited Medium: Print ISSN: 0578-1426 (Print) Linking ISSN: 05781426 NLM ISO Abbreviation: Zhonghua Nei Ke Za Zhi Subsets: MEDLINE

مواضيع طبية MeSH: Cholangiocarcinoma*/drug therapy , Quinolines*/administration & dosage , Quinolines*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Phenylurea Compounds*/administration & dosage , Phenylurea Compounds*/therapeutic use , Bile Duct Neoplasms*/drug therapy, Humans ; Retrospective Studies ; Male ; Female ; Infusions, Intra-Arterial ; Gemcitabine ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/administration & dosage ; Middle Aged ; Oxaliplatin/administration & dosage ; Oxaliplatin/therapeutic use ; Hepatic Artery ; Aged ; Treatment Outcome

المؤلفون: Kumondai M; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan., Ogawa R; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan., Hayashi N; Faculty of Pharmaceutical Sciences, Tohoku University, Sendai, Japan., Ishida Y; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan., Oshikiri H; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan., Sato Y; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan., Kikuchi M; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan.; Faculty of Pharmaceutical Sciences, Tohoku University, Sendai, Japan., Sato Y; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan., Sato T; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan., Maekawa M; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan.; Faculty of Pharmaceutical Sciences, Tohoku University, Sendai, Japan., Mano N; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan.; Faculty of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.

المصدر: Pharmacology research & perspectives [Pharmacol Res Perspect] 2024 Aug; Vol. 12 (4), pp. e1241.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 101626369 Publication Model: Print Cited Medium: Internet ISSN: 2052-1707 (Electronic) Linking ISSN: 20521707 NLM ISO Abbreviation: Pharmacol Res Perspect Subsets: MEDLINE

مواضيع طبية MeSH: Phenylurea Compounds*/urine , Phenylurea Compounds*/pharmacokinetics , Phenylurea Compounds*/blood , Phenylurea Compounds*/therapeutic use , Phenylurea Compounds*/administration & dosage , Quinolines*/urine , Quinolines*/therapeutic use , Quinolines*/blood , Quinolines*/administration & dosage , Quinolines*/pharmacokinetics , Cytochrome P-450 CYP3A*/metabolism , Biomarkers*/urine , Biomarkers*/blood , Drug Monitoring*/methods, Humans ; Female ; Aged ; Middle Aged ; Male ; Adult ; Aged, 80 and over ; Antineoplastic Agents/urine ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/blood ; Antineoplastic Agents/pharmacokinetics ; Protein Kinase Inhibitors/urine ; Protein Kinase Inhibitors/blood ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/pharmacokinetics ; Protein Kinase Inhibitors/administration & dosage ; Neoplasms/drug therapy ; Neoplasms/blood ; Neoplasms/urine ; Tandem Mass Spectrometry/methods ; Endometrial Neoplasms/drug therapy ; Endometrial Neoplasms/urine ; Endometrial Neoplasms/blood ; Carcinoma, Hepatocellular/drug therapy ; Carcinoma, Hepatocellular/blood ; Carcinoma, Hepatocellular/urine ; Chromatography, Liquid/methods ; Thyroid Neoplasms/drug therapy ; Thyroid Neoplasms/urine ; Thyroid Neoplasms/blood ; Liver Neoplasms/drug therapy ; Liver Neoplasms/blood ; Liver Neoplasms/urine ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/urine ; Carcinoma, Renal Cell/blood ; Hydrocortisone/analogs & derivatives

المؤلفون: Liu X; School of Basic Medicine, College of Electronic Information, Micro-Nano Technology College, Qingdao University, Qingdao, China., Gao X; School of Basic Medicine, College of Electronic Information, Micro-Nano Technology College, Qingdao University, Qingdao, China., Yang Y; Department of Infectious Diseases, Affiliated Hospital of Qingdao University, Qingdao, China., Yang D; School of Basic Medicine, College of Electronic Information, Micro-Nano Technology College, Qingdao University, Qingdao, China., Guo Q; Clinical Laboratory, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China., Li L; School of Basic Medicine, College of Electronic Information, Micro-Nano Technology College, Qingdao University, Qingdao, China., Liu S; Department of Clinical Medicine, Qingdao Medical College, Qingdao University, Qingdao, China., Cong W; Department of Clinical Medicine, Qingdao Medical College, Qingdao University, Qingdao, China., Lu S; Department of Medical Laboratory, Qingdao Medical College, Qingdao University, Qingdao, China., Hou L; School of Basic Medicine, College of Electronic Information, Micro-Nano Technology College, Qingdao University, Qingdao, China., Wang B; School of Basic Medicine, College of Electronic Information, Micro-Nano Technology College, Qingdao University, Qingdao, China., Li N; School of Basic Medicine, College of Electronic Information, Micro-Nano Technology College, Qingdao University, Qingdao, China. ning-99@163.com.

المصدر: Apoptosis : an international journal on programmed cell death [Apoptosis] 2024 Aug; Vol. 29 (7-8), pp. 1161-1184. Date of Electronic Publication: 2024 May 14.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Country of Publication: Netherlands NLM ID: 9712129 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-675X (Electronic) Linking ISSN: 13608185 NLM ISO Abbreviation: Apoptosis Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/genetics , Carcinoma, Hepatocellular*/metabolism , Carcinoma, Hepatocellular*/pathology , Quinolines*/pharmacology , Quinolines*/therapeutic use , Liver Neoplasms*/drug therapy , Liver Neoplasms*/genetics , Liver Neoplasms*/metabolism , Liver Neoplasms*/pathology , Phenylurea Compounds*/pharmacology , Phenylurea Compounds*/therapeutic use , Drug Resistance, Neoplasm*/genetics , Drug Resistance, Neoplasm*/drug effects , Tumor Suppressor Protein p53*/metabolism , Tumor Suppressor Protein p53*/genetics , Phosphatidylinositol 3-Kinases*/metabolism , Phosphatidylinositol 3-Kinases*/genetics , Signal Transduction*/drug effects , Proto-Oncogene Proteins c-akt*/metabolism , Proto-Oncogene Proteins c-akt*/genetics, Humans ; Animals ; Cell Line, Tumor ; Mice ; Apoptosis/drug effects ; Cell Proliferation/drug effects ; Mice, Nude ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Gene Expression Regulation, Neoplastic/drug effects ; Male ; Xenograft Model Antitumor Assays ; Mice, Inbred BALB C ; Proto-Oncogene Proteins c-mdm2/metabolism ; Proto-Oncogene Proteins c-mdm2/genetics ; Female

المؤلفون: Yang D; Department of Radiation Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing., Li X; Thoracic Radiotherapy Ward 2, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan., Xue X; Department of Radiotherapy, The Second Hospital of Hebei Medical University, Shijiazhuang., Jiang L; Department of Radiation Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing., Shi A; Department of Radiation Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing., Zhao J; Department of Thoracic Oncology I, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.

المصدر: Anti-cancer drugs [Anticancer Drugs] 2024 Aug 01; Vol. 35 (7), pp. 680-685. Date of Electronic Publication: 2024 May 03.

نوع المنشور: Journal Article; Multicenter Study; Randomized Controlled Trial; Clinical Trial, Phase II

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5741 (Electronic) Linking ISSN: 09594973 NLM ISO Abbreviation: Anticancer Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/therapy , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/therapy , Indoles*/administration & dosage , Indoles*/therapeutic use , Indoles*/adverse effects , Quinolines*/therapeutic use , Quinolines*/administration & dosage , Quinolines*/adverse effects , Chemoradiotherapy*/methods, Humans ; Middle Aged ; Male ; Female ; Aged ; Adult ; Consolidation Chemotherapy/methods ; Neoplasm Staging ; Progression-Free Survival ; Survival Rate

المؤلفون: An T; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Hui Q; Department of HPB Surgery, Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing, China., Zong H; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Liu L; Dongguan Key Laboratory of Environmental Medicine, School of Public Health, Guangdong Medical University, Dongguan, China., Cao X; Department of Digestive Disease, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Li R; Department of Respiratory Intervention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China., Hu S; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Liu Y; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Li J; Department of Integrated Chinese and Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. zlyylijia4420@zzu.edu.cn., Zhao R; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. zrh_ly@163.com.

المصدر: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Aug; Vol. 26 (8), pp. 2006-2019. Date of Electronic Publication: 2024 Mar 26.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Quinolines*/therapeutic use , Quinolines*/adverse effects , Quinolines*/administration & dosage , Biliary Tract Neoplasms*/drug therapy , Biliary Tract Neoplasms*/pathology , Biliary Tract Neoplasms*/mortality , Indoles*/therapeutic use , Indoles*/administration & dosage , Indoles*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/adverse effects , Immune Checkpoint Inhibitors*/administration & dosage, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Progression-Free Survival ; Retrospective Studies ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Aged, 80 and over

المؤلفون: Qin Y; Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital), Zhuhai, Guangdong, China., Han S; Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital), Zhuhai, Guangdong, China., Yu Y; Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital), Zhuhai, Guangdong, China., Qi D; Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital), Zhuhai, Guangdong, China., Ran M; Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital), Zhuhai, Guangdong, China.; School of Pharmacy, Guangdong Medical University, Zhanjiang, China., Yang M; Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital), Zhuhai, Guangdong, China., Liu Y; Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital), Zhuhai, Guangdong, China., Li Y; Department of Nephrology, First Affiliated Hospital of Jinan University, Guangzhou, China., Lu L; Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital), Zhuhai, Guangdong, China., Liu Y; Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital), Zhuhai, Guangdong, China., Li Y; Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital), Zhuhai, Guangdong, China.

المصدر: Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2024 Aug; Vol. 44 (8), pp. 1808-1831. Date of Electronic Publication: 2024 May 03.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 101160857 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1478-3231 (Electronic) Linking ISSN: 14783223 NLM ISO Abbreviation: Liver Int Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Hepatocellular*/drug therapy , Quinolines*/therapeutic use , Quinolines*/pharmacology , Phenylurea Compounds*/therapeutic use , Liver Neoplasms*/drug therapy , Liver Neoplasms*/pathology , Drug Resistance, Neoplasm* , Antineoplastic Agents*/therapeutic use, Humans ; Tumor Microenvironment/drug effects ; Epithelial-Mesenchymal Transition/drug effects ; Neoplastic Stem Cells/drug effects ; Protein Kinase Inhibitors/therapeutic use

المؤلفون: Aggrey MO; Department of Pharmacognosy and Herbal Medicine, University of Health and Allied Sciences, Ho, Ghana., Wang WQ; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China., Xuan LJ; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.

المصدر: Natural product research [Nat Prod Res] 2024 Aug; Vol. 38 (16), pp. 2756-2762. Date of Electronic Publication: 2023 Jul 10.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Taylor & Francis Health Sciences Country of Publication: England NLM ID: 101167924 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1478-6427 (Electronic) Linking ISSN: 14786419 NLM ISO Abbreviation: Nat Prod Res Subsets: MEDLINE

مواضيع طبية MeSH: Glycosides*/chemistry , Glycosides*/isolation & purification , Quinolines*/chemistry , Quinolines*/isolation & purification , Plant Roots*/chemistry , Cryptolepis*/chemistry, Molecular Structure ; Alkaloids/chemistry ; Alkaloids/isolation & purification ; Plant Extracts/chemistry ; Indole Alkaloids/chemistry ; Indole Alkaloids/isolation & purification

المؤلفون: Yang M; Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518117, China., Wang JJ; Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518117, China., Deng SQ; Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518117, China., Liang SS; Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518117, China., Sun L; Department of Gynecological Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

المصدر: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2024 Jul 23; Vol. 46 (7), pp. 696-702.

نوع المنشور: English Abstract; Journal Article

بيانات الدورية: Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium: Print ISSN: 0253-3766 (Print) Linking ISSN: 02533766 NLM ISO Abbreviation: Zhonghua Zhong Liu Za Zhi Subsets: MEDLINE

مواضيع طبية MeSH: Indazoles*/adverse effects , Indazoles*/therapeutic use , Ovarian Neoplasms*/drug therapy , Indoles*/adverse effects , Indoles*/administration & dosage , Indoles*/therapeutic use , Drug Resistance, Neoplasm* , Piperidines*/adverse effects , Piperidines*/administration & dosage , Piperidines*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Quinolines*/adverse effects , Quinolines*/therapeutic use , Quinolines*/administration & dosage , Neoplasm Recurrence, Local*/drug therapy, Humans ; Female ; Platinum/therapeutic use ; Progression-Free Survival ; Adult ; Middle Aged ; Aged ; BRCA1 Protein/genetics ; Poly(ADP-ribose) Polymerase Inhibitors/adverse effects ; Poly(ADP-ribose) Polymerase Inhibitors/administration & dosage ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; BRCA2 Protein/genetics